dihexa bbb permeability For patients with myotonic dystrophy type 1 ― a rare, dominantly inherited, progressive disorder that affects multiple organ systems and results in decreased life expectancy ― there are currently no approved therapies Frontiers | Pathophysiology of Blood–Brain

Systemic adverse effects appear to be uncommon based on available reports, but comprehensive adverse event profiles are lacking due to the paucity of large-scale clinical investigations

Beyond that, the evidence is per-compound plus the CagriSema (cag + sema) Phase 3 data as the closest human analog

Thus, based on the understanding of the role of the HGF/c-Met signaling pathway and the uniqueness of c-Met in HCC, more and more therapeutic strategies target c-Met and the interaction between c-Met and downstream signaling mediators instead of the interaction between HGF and c-Met because of the varying activation of c-Met

In the latest clinical trial, OS and progression-free survival (PFS) in months was calculated for Phase 2 of Tepotinib 500 mg (5.55 and 3.22 months, respectively) (NCT02115373)